Compare GSK plc (GSK) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Phillips 66 — how do they compare? GSK plc trades at $50.44 (market cap $102.60B), while Phillips 66 trades at $226.59 (market cap $89.52B). The key difference: GSK plc and Phillips 66 are close in size by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | PSX | |
|---|---|---|
Market Cap | $102.60B | $89.52B |
Sector | Health | Energy |
52-Week High | $61.18 | $224.36 |
52-Week Low | $38.22 | $120.04 |
Enterprise Value | $123.04B | $105.99B |
Dividend Yield | 3.57% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Phillips 66 (PSX) trades at $225.04, up 4.41% today, reflecting strong momentum after Q2 2026 earnings beat. The stock shows bullish technical signals with support near $220 and resistance at $227. Fundamentally, the company reported robust Q2 EPS of $9.41, exceeding estimates, driven by high refining margins and operational efficiency. Recent news highlights a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream assets.
Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a price target of $221.92. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical factors affecting energy markets. The stock's valuation metrics, like P/E of 12.81, suggest room for upside if earnings trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
